Pyxis Oncology Inc (NASDAQ: PYXS) is a clinical-stage biotechnology company focused on developing next-generation cancer therapies. By harnessing the power of antibody-drug conjugates (ADCs) and immuno-oncology approaches, the company aims to create targeted treatments that improve outcomes for cancer patients. With a commitment to scientific innovation and precision medicine, Pyxis Oncology is advancing a pipeline of novel therapies designed to enhance the effectiveness and safety of cancer treatments. As it progresses through clinical trials, the company remains dedicated to transforming oncology care with cutting-edge biopharmaceutical solutions.
Latest shares articles
UK economy outpaces gloomy forecasts, yet caution remains
The UK economy grew more than expected in Q1 despite warnings about a recession, but the outlook remains clouded by the threat of tariffs
08:08, 15 May 2025
Barrick Gold forecast: Third-party price target
Discover the Barrick Gold (GOLD) price predictions for 2025 and beyond, with analyst price targets and more on Capital.com
15:05, 8 May 2025
US stocks hold ground despite Powell’s stagflation warning
US equities continue to attract buying interest backed by improved market sentiment despite Powell's warning about stagflation
11:29, 8 May 2025
Alibaba price forecast: Third-party price targets
On 26 March 2025, the price of Alibaba (BABA) shares had increased by approximately 57.49% year-to-date (YTD) and 89.75% year on year.
10:15, 30 April 2025
Ratings and Reviews
Ratings and Reviews
